We can’t show the full text here under this license. Use the link below to read it at the source.
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
Use of Blood Sugar Medicines in People with Type 2 Diabetes and Heart Disease or Risk of Heart Disease
AI simplified
Abstract
The percentage of patients using sodium-glucose co-transporter-2 inhibitors (SGLT-2is) among those aged ≥ 65 years with type 2 diabetes and cardiovascular disease increased from 1.1% in 2015 to 3.4% in 2019.
- Utilization of SGLT-2is and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients aged 50-64 years with type 2 diabetes and cardiovascular disease increased from 2015 to 2019.
- In the CVD cohort aged 50-64 years, SGLT-2is usage rose from 2.6% to 7.3%, while GLP-1 RAs usage increased from 4.3% to 10.1%.
- Among patients aged ≥ 65 years, utilization of GLP-1 RAs with proven cardiovascular benefit increased from 1.2% to 3.8% in the CVD cohort.
- Despite these increases, overall use of SGLT-2is and GLP-1 RAs remained low across all age groups during the study period.
- Similar trends were observed in the CVD risk cohort, with SGLT-2is usage among those aged 50-64 years rising from 3.3% to 6.8%.
AI simplified
Key numbers
3.4%
Increase in SGLT-2 Inhibitor Use (≥ 65 years)
Percentage of patients aged ≥ 65 years with CVD using SGLT-2 inhibitors in 2019.
7.3%
Increase in SGLT-2 Inhibitor Use (50-64 years)
Percentage of patients aged 50-64 years with CVD using SGLT-2 inhibitors in 2019.
1.1-3.4%
Low Overall Utilization of GLAs (≥ 65 years)
Percentage range of patients aged ≥ 65 years using GLAs with proven cardiovascular benefits from 2015 to 2019.